Answers are grounded in this paper and cite their sources.
The initial effectiveness of anticancer treatment is often undermined by tumor cell adaptation to therapeutic pressure. Epigallocatechin-3-gallate (EGCG), the principal catechin in green tea, has shown potential to restore drug sensitivity in resistant cancer cells. Previous reviews have broadly described its anticancer activities. Here, we focus on experimentally established acquired drug-resistant cancer models, distinguishing evidence for resistance reversal from general enhancement of anticancer drug activity. We also examine EGCG derivatives and nanoplatform-based delivery systems, alongside epidemiological and early clinical findings. Studies in resistant models indicate that EGCG can reduce drug efflux, inhibit pro-survival signaling, promote apoptosis, alter epigenetic regulation, and enhance drug-induced DNA damage. EGCG can also suppress epithelial–mesenchymal transition, cancer stem cell-like properties, and invasive phenotypes. Structural modification and delivery systems may improve the stability, bioavailability, tumor targeting, and therapeutic efficacy. However, evidence for reversal remains largely preclinical, and direct clinical validation in patients with treatment-resistant cancers is lacking. Further development requires formulations that achieve adequate tumor exposure and studies that establish whether the effects observed in experimental models translate into improved treatment responses in drug-resistant cancers.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: